Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT02523092
PHASE4
Use of CXCL9 as a Biomarker of Acthar Efficacy
Sponsor: University of California, San Francisco
View on ClinicalTrials.gov
Summary
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
14
Start Date
2022-11-03
Completion Date
2026-12
Last Updated
2023-05-11
Healthy Volunteers
No
Conditions
Interventions
DRUG
Acthar gel
Acthar gel given IM or SQ as per package insert
Locations (1)
University of California, San Francisco
San Francisco, California, United States